All In Biotech

Free tool

FAERS Monitor: Betapace Af

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021151 or its brand name (Betapace Af, Sotalol Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

2,600

Serious

2,156

83% of reports

Hospitalization

1,143

Death reported

260

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • atrial fibrillation186
  • drug ineffective151
  • electrocardiogram qt prolonged149
  • hypotension125
  • dyspnoea119
  • dizziness116
  • bradycardia112
  • drug interaction99
  • fatigue97
  • nausea95
  • fall87
  • off label use73
  • ventricular tachycardia73
  • acute kidney injury72
  • asthenia65

Reports by year received

View as table
YearReports
200453
200532
2006128
2007237
200843
2009128
201036
201190
2012111
201363
201470
201556
201680
201798
2018124
2019147
2020112
202195
2022142
2023152
2024194
2025254
2026155

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,559 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
ventricular tachycardiaSignal7335.928.62,434
electrocardiogram qt prolongedSignal14933.628.84,676
bradycardiaSignal11217.114.31,685
atrial fibrillationSignal18615.513.52,511
drug interactionSignal995.14.2320
hypotensionSignal1255.04.3405
acute kidney injurySignal723.83.0147
fallSignal872.11.751
dizziness1161.91.648
dyspnoea1191.71.435
asthenia651.41.17
fatigue971.00.80
nausea951.00.80
drug ineffective1510.90.81
off label use730.70.512

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.